Muscarinic receptor type 1 (M1) stimulation, probably through KCNQ/Kv7 channel closure, increases spontaneous GABA release at the dendrodendritic synapse in the mouse accessory olfactory bulb.
Cholinergic modulation of spontaneous GABAergic currents (mIPSC) was studied using whole-cell patch methods in mouse accessory olfactory bulb slices. Carbachol (above 100 microM) administration produced an increase in the mIPSC frequency in mitral cells, but did not affect the responses of mitral cells to GABA. The carbachol effect persisted in the presence of combined ionotropic and metabotropic glutamatergic receptor antagonists. The carbachol effect was reduced by the muscarinic receptor type-1 and -4 (M1 and M4) antagonist pirenzepine (10 microM), but not by the M2 and M4 antagonist himbacine (10 microM). The KCNQ/Kv7 potassium channel openers retigabine (80 microM) and diclofenac (300 microM) blocked the carbachol action, while the KCNQ potassium channel blocker XE-911 (20 microM) increased the mIPSC frequency. XE-911's action persisted in the presence of glutamate receptor blockers. In the presence of carbachol, mIPSCs were abolished by Ni (200 microM), while being insensitive to the calcium channel blocker nimodipine (30 microM), suggesting a role for R-type calcium channels in the GABA release. These results suggest that carbachol closed KCNQ channels by stimulating M1 receptors on granule cell dendrites, and the resulting depolarized and unstable membrane promoted calcium influx, thus increasing the GABA release. The possible role of acetylcholine in facilitating formation of a pheromone memory in mice is also discussed.
Takahashi
Yoshito
Y
Department of Physiology, Kochi Medical School, Nankoku, Kochi, Japan. yuutarot@yahoo.co.jp
Kaba
Hideto
H
D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020908:Calcium Channels, R-Type / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D018679:Cholinergic Agonists / Q000494:pharmacology; D003712:Dendrites / Q000378:metabolism; D004008:Diclofenac / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005663:Furans / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology; D051656:KCNQ Potassium Channels / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D009553:Nimodipine / Q000494:pharmacology; D009830:Olfactory Bulb / Q000166:cytology*; D018408:Patch-Clamp Techniques; D010655:Phenylenediamines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D010890:Pirenzepine / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D043643:Receptor, Muscarinic M1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D017470:Receptors, Glutamate; D013569:Synapses / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000470:Alkaloids; D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D020908:Calcium Channels, R-Type; D002219:Carbamates; D018679:Cholinergic Agonists; D018691:Excitatory Amino Acid Antagonists; D005663:Furans; D018756:GABA Antagonists; D051656:KCNQ Potassium Channels; D018727:Muscarinic Antagonists; D009281:Naphthalenes; D010655:Phenylenediamines; D010880:Piperidines; D026902:Potassium Channel Blockers; D043643:Receptor, Muscarinic M1; D017470:Receptors, Glutamate; C101866:ezogabine; D004008:Diclofenac; D010890:Pirenzepine; D005680:gamma-Aminobutyric Acid; D009553:Nimodipine; D002217:Carbachol; C048172:himbacine; D002118:Calcium